EGC Innova Spółka z Ograniczoną Odpowiedzialnością (KRS 0000367283, NIP 7292685616) is a Polish company, headquartered in M. Łódź, Łódzkie voivodeship. EGC Innova operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since October 6, 2010. EGC Innova's most recently reported net revenue was 0 PLN for 2025.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - EGC Innova
Identity
- Name
- EGC Innova Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- October 6, 2010
- Registry status as of
- June 26, 2026
- Latest entry
- June 26, 2026
- Founding act
- 19.07.2010 R. KANCELARIA NOTARIALNA W ŁODZI NOTARIUSZ BOGNA GAŁĄZKA-MIKINA REPERTORIUM A NR 3476/2010- UMOWA SPÓŁKI
Articles of association history (3)
- July 19, 2010: 19.07.2010 R. KANCELARIA NOTARIALNA W ŁODZI NOTARIUSZ BOGNA GAŁĄZKA-MIKINA REPERTORIUM A NR 3476/2010- UMOWA SPÓŁKI
- June 22, 2011: 22.06.2011R., REPERTORIUM A NR 3464/2011, NOTARIUSZ BOGNA GAŁĄZKA-MIKINA, KANCELARIA NOTARIALNA W ŁODZI, ZMIENIONO § 6 USTĘP 1 UMOWY SPÓŁKI.
- March 19, 2013: 19.03.2013 R., NOTARIUSZ BOGNA GAŁĄZKA-MIKINA, KANCELARIA NOTARIALNA W ŁODZI, REPERTORIUM A NR 1899/2013, ZMIENIONO § 6 UMOWY SPÓŁKI.
Activities
Other activities
Address and contact
- Address
- ŻELIGOWSKIEGO, 3/5, 90-752, M. ŁÓDŹ, POLSKA
- Voivodeship
- ŁÓDZKIE
- District
- M. ŁÓDŹ
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - EGC Innova
Credibility rating
55.5 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/16 yrs
Board changes
1
1/16 yrs
PKD changes
3
3/16 yrs
Name changes
0
0/16 yrs
Data from 16 years of registry activity.
Credibility history
Payment reliability score from 2018–2025
Current: C (56/100)
Trend: stable (+2.0 pts/year)
Moderate payment credibility - the company is able to meet its obligations, but some indicators warrant caution.
Trade credit limit history
Standard limit from 2018–2025
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - EGC Innova
Founded
October 6, 2010
15 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
M. ŁÓDŹ
ŁÓDZKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
6.0 K PLN
120 shares total
Shareholders
4
shareholders
Board
1 person
Filed years
5 years
2018–2025 · profitable: 0/5
Registry entries
27
latest: June 26, 2026
Revenue
0 PLN
2025
Net profit
0 PLN
2025
Assets
10.9 K PLN
2025
Equity
10.9 K PLN
2025
EBITDA
N/A
2025
no depreciation data
Valuation
7.6 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - EGC Innova.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
